Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIPARP | Q7Z3E1 | 11/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968344 | 1.00 | TIPARP (0.42) | TIPARPCHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL24968356 | 1.00 | TIPARP (0.42) | TIPARPCHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL24968343 | 1.00 | TIPARP (0.42) | TIPARPCHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL24968349 | 0.93 | WDR5 (0.37) | TIPARPCHRM2CHRM1 | |
| SCHEMBL24968347 | 0.93 | WDR5 (0.37) | TIPARPCHRM2CHRM1 | |
| SCHEMBL24968235 | 0.93 | WDR5 (0.37) | TIPARPCHRM2CHRM1 | |
| SCHEMBL24968241 | 0.91 | ACACB (0.35) | TIPARPCHRM2CHRM1CHRM4 | |
| SCHEMBL24968240 | 0.91 | ACACB (0.35) | TIPARPCHRM2CHRM1CHRM4 | |
| SCHEMBL24968457 | 0.91 | ACACB (0.35) | TIPARPCHRM2CHRM1CHRM4 | |
| SCHEMBL27233753 | 0.90 | GPR119 (0.40) | TIPARPCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006013-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | TIPARP 142/4885CHRM2 4881/4885CHRM1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.